TLR9 and myeloid leukemia: For example, in a recent work, myeloid cell-selective inhibition of NF-κB was achieved using a mimic oligonucleotide of miR146a conjugated to CpG motif to act as an agonist for Toll-like receptor 9 (TLR9), which allowed to knock down inflammatory and tumorigenic NF-κB activity in macrophages and myeloid leukemia in both in-vitro and in-vivo conditions (150).